Based on the provided conference call transcript, the company had an outstanding quarter with strong performance in terms of key financial metrics. Non-GAAP EPS was reported to be $0.84, which represents an increase of $0.10 over the first quarter of the previous year. Additionally, revenue grew by 12%, with double-digit growth across key growth drivers.

Specifically, in terms of product sales, Opdivo, a drug used in the treatment of cancer, showed strong performance despite facing a more competitive landscape in the U.S. for lung cancer. The company mentioned that while they experienced some share loss in lung cancer, their share has shown signs of stabilization in recent weeks. Outside of lung cancer, sales were strong across other indications including renal, melanoma, head and neck, and bladder. The company also reported making significant progress from a regulatory perspective, including new approvals and positive recommendations for the drug in various markets.

The company also highlighted the progress made in their business development activities, investing in translational capabilities through various deals and agreements. Additionally, they emphasized the importance of their diversified portfolio, with encouraging data from their FGF21 for NASH at a recent liver conference, and the expectation of initiating a registrational program for the drug.

In terms of their financial performance, the company highlighted the continued strong performance of their drug Eliquis in the U.S. and other key markets, as well as the double-digit growth of Orencia and Sprycel. Eliquis specifically exceeded $1 billion in revenue for the quarter and is the leading NOAC in the U.S.

The company also discussed their balanced approach to capital allocation, with business development continuing to be a priority. They mentioned their sourcing of external opportunities across preclinical and clinical areas, as well as building their translational capabilities.

Overall, the company expressed confidence in their current financial position, commercial performance, and clinical pipeline, indicating a strong outlook for the future. They highlighted their industry-leading portfolio and the potential of their pipeline in driving future value for their products. They also mentioned plans to present additional data from their immuno-oncology assets and various other developments at upcoming conferences.

In conclusion, the company appears to be in a strong financial position with a promising pipeline and a focus on continued growth and innovation in the healthcare industry.